154 related articles for article (PubMed ID: 37006064)
21. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
23. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
25. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
27. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis.
Wang K; Ren Y; Ma Z; Li F; Cheng X; Xiao J; Zhang S; Yu Z; Yang H; Zhou H; Li Y; Liu H; Jiao ZY
Cancer Manag Res; 2019; 11():3009-3020. PubMed ID: 31114348
[No Abstract] [Full Text] [Related]
29. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
32. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer.
Lan YQ; Wu RP; Huang XB; Wang XL; Zhong DT; Huang CY; Song JT
Tumori; 2018; 104(1):22-29. PubMed ID: 28777427
[TBL] [Abstract][Full Text] [Related]
34. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
35. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
Di Lauro L; Vici P; Belli F; Tomao S; Fattoruso SI; Arena MG; Pizzuti L; Giannarelli D; Paoletti G; Barba M; Sergi D; Maugeri-Saccà M
Gastric Cancer; 2014 Oct; 17(4):718-24. PubMed ID: 24318671
[TBL] [Abstract][Full Text] [Related]
37. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Hofheinz RD; Merx K; Haag GM; Springfeld C; Ettrich T; Borchert K; Kretzschmar A; Teschendorf C; Siegler G; Ebert MP; Goekkurt E; Mahlberg R; Homann N; Pink D; Bechstein W; Reichardt P; Flach H; Gaiser T; Battmann A; Oduncu FS; Loose M; Sookthai D; Pauligk C; Göetze TO; Al-Batran SE
J Clin Oncol; 2022 Nov; 40(32):3750-3761. PubMed ID: 35709415
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Lordick F; Lorenzen S; Stollfuss J; Vehling-Kaiser U; Kullmann F; Hentrich M; Zumschlinge R; Dietzfelbinger H; Thoedtmann J; Hennig M; Seroneit T; Bredenkamp R; Duyster J; Peschel C
Br J Cancer; 2005 Jul; 93(2):190-4. PubMed ID: 16012522
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of FLOT regimen
Farrokhi P; Sadeghi A; Sharifi M; Riechelmann R; Moghaddas A
Res Pharm Sci; 2022 Dec; 17(6):621-634. PubMed ID: 36704436
[TBL] [Abstract][Full Text] [Related]
40. Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.
Forouhari A; Moghaddas A; Darakhshandeh A
J Res Med Sci; 2023; 28():79. PubMed ID: 38292337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
